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Abstract
Purpose—Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to 
assess patient safety, as well as inform decisions related to treatment and continued trial 
participation. As prior research has demonstrated that conventional concordance metrics (e.g., 
intraclass correlation) may not capture nuanced aspects of the association between clinician and 
patient-graded AEs, we aimed to characterize differences in AE grading thresholds between 
doctors (MDs), registered nurses (RNs), and patients using the Bayesian Graded Item Response 
Model (GRM).
Methods—From the medical charts of 393 patients aged 26–91 (M = 62.39; 43% male) receiving 
chemotherapy, we retrospectively extracted MD, RN and patient AE ratings. Patients reported 
using previously developed Common Terminology Criteria for Adverse Events (CTCAE) patient-
language adaptations called STAR (Symptom Tracking and Reporting). A GRM was fitted to 
calculate the latent grading thresholds between MDs, RNs and patients.
Results—Clinicians have overall higher average grading thresholds than patients when assessing 
diarrhea, dyspnea, nausea and vomiting. However, RNs have lower grading thresholds than 
patients and MDs when assessing constipation. The GRM shows higher variability in patients’ AE 
grading thresholds than those obtained from clinicians.
Conclusions—The present study provides evidence to support the notion that patients report 
some AEs that clinicians might not consider noteworthy until they are more severe. The 
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availability of GRM methodology could serve to enhance clinical understanding of the patient 
symptomatic experience and facilitate discussion where AE grading discrepancies exist. Future 
work should focus on capturing explicit AE grading decision criteria from MDs, RNs, and 
patients.
Keywords
Patient-reported outcomes; Adverse events; Clinical trials; Clinician–patient agreement; Item 
response theory; Neoplasms
Introduction
Accurate capture and monitoring of symptomatic adverse events (AE) is essential in clinical 
trials and drug labeling to ensure patient safety and inform treatment-related decision-
making (Basch 2010, 2014, 2016). In the United States, the standard approach to collecting 
this information as part of trials in oncology is clinician reporting using the Common 
Terminology Criteria for Adverse Events (CTCAE) (National Cancer Institute 2010), which 
allows licensed clinicians [i.e., medical doctors (MDs) and registered nurses (RNs)] to grade 
AEs based upon descriptive clinical criteria (e.g., Grade 3 nausea = inadequate oral caloric 
or fluid intake; tube feeding, TPN, or hospitalization indicated). The assignment of a given 
AE grade has implications for patient treatment and/or participation in clinical trials.
The CTCAE includes multiple categories of AEs, including lab-based, which are generally 
sourced directly from lab reports (e.g., neutropenia); clinical measurement-based, which are 
typically evaluated and reported by clinicians (e.g., hypertension); symptom-based such as 
fatigue or nausea, which despite being amenable to patient reporting, are still primarily rated 
by clinicians (Basch et al. 2014).
The increased acceptance of the use of patient-reported outcomes (PROs), defined as the 
unfiltered direct report of a given symptom by a patient (Basch 2012; Trotti et al. 2007), to 
characterize the patient symptomatic experience has led to the US National Cancer 
Institute’s initiative to develop a PRO version of the CTCAE (PRO-CTCAE) that will be 
used in future US-based clinical trials in oncology (Basch et al. 2014; Dueck et al. 2015; 
Hay et al. 2014). Given that both clinician- and patient-based reporting of symptomatic AEs 
will be commonplace in US-based oncology clinical trials, it is important to understand how 
these independent rating sources are associated before this information can be integrated into 
clinical practice.
As part of our prior work making use of conventional statistical metrics [e.g., intraclass 
correlation (ICC), Cohen’s weighted κ] to compare clinician and patient reports of AE 
severity using an ordinal response scale, we have observed that the inter-rater agreement is 
highly dependent on the prevalence of the AE; a high proportion of “asymptomatic” pairs of 
ratings (i.e., both ratings are 0, or not present) may lead to an inflated level of agreement, 
which may not necessarily be an accurate representation of the subset of patients who are 
experiencing any levels of the symptom (Atkinson et al. 2012, 2016).
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An alternative Bayesian approach to the calculation of concordance known as the Graded 
Item Response Model (GRM) was recently proposed by Baldwin and colleagues (Baldwin et 
al. 2009). This approach utilized the underlying principles of the original Samejima GRM 
(Samejima 1997) in a Bayesian framework. In this example, patient hip fracture radiograms 
were independently judged by 12 orthopedic surgeons using a four-level classification of 
severity. Surgeons’ hip fracture severity ratings were viewed from an Item Response Theory 
(IRT) perspective, in which each surgeon’s severity rating was modeled as a scale item while 
radiographs from patients were considered as a sample from a latent continuum of hip 
fracture severity. This analytic framework allowed an IRT analysis on the raw rectangular 
dataset from 15 patients evaluated by 12 surgeons (likened to scale items). The item 
threshold parameters in the fitted Bayesian GRM represented the surgeons’ decision cutoffs 
and the item discrimination represented how sensitive the surgeons’ responses were with 
respect to changes in hip fracture severity. The authors found that the model-predicted 
decision cutoffs agreed with surgeons’ severity ratings reasonably well. This example 
showed that the Bayesian GRM framework has a potential application for identifying how 
raters differ in their independent assessments, which may be subtle in the sense that such 
differences can be nuanced and highly contextual (e.g., concordance at low latent hip 
fracture severity, with discordance emerging at high latent hip fracture severity).
The present study applied this Bayesian GRM framework to measuring concordance 
between doctor (MD)-, registered nurse (RNs)-, and patient-based reporting of symptomatic 
AEs. We sought to model and further characterize nuanced differences in AE grading 
thresholds between MDs, RNs, and patients using this advanced statistical technique, thus 
providing us with information beyond that which can be obtained through the use of 
traditional statistical methods such as Cohen’s weighted κ or ICC.
Methods
Patients
The data sample for this secondary analysis included 393 English-language speaking cancer 
patients of mixed disease type (i.e., lung, prostate, and gynecologic) who were undergoing 
chemotherapy regimens as part of an Institutional Review Board approved protocol at 
Memorial Sloan Kettering Cancer Center (MSK) between March 2005 and August 2009 
where informed consent was obtained from all included patients (Basch et al. 2005, 2007a, 
b, 2009, 2016). Patient records were eligible for inclusion in this analysis if they contained 
documented independent MD, RN, and patient symptom ratings for a single clinic visit, 
without any other restrictions (Atkinson et al. 2012).
Measures
Common Terminology Criteria for Adverse Events version 4 (CTCAE) 
(National Cancer Institute 2010)—CTCAE consists of a library of over 700 descriptive 
terms for clinician- based assessment of patient AEs related to cancer treatment. Each 
CTCAE term is assessed using a 5-point verbal descriptor grading scale, with each grade 
following a similar grading convention (i.e., 0 = not present, 1 = mild, 2 = moderate, 3 = 
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severe and/or requiring medical intervention but not life-threatening, 4 = life-threatening 
consequences, and 5 = death).
Symptom Tracking and Reporting (STAR) (Basch et al. 2005, 2007a, b, 2009, 
2015, 2016)—STAR is a web-based adaptation of CTCAE that was developed and 
validated to facilitate clinic waiting area and between-visit home-based patient reporting of 
treatment-related AEs. STAR items are assessed using a 5-point verbal descriptor rating 
scale similar to CTCAE (i.e., 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = disabling). 
STAR items assessing constipation, diarrhea, dyspnea, fatigue, nausea, and vomiting were 
included in the present analysis to correspond with analogous clinician-based CTCAE 
ratings of patients for these AEs.
Procedure
Routinely documented patient electronic medical records were examined using the Health 
Information System of MSK. Data were abstracted in cases where ratings of constipation, 
diarrhea, dyspnea, fatigue, nausea, and vomiting were made by an independent MD (via 
CTCAE), RN (via CTCAE), and patient (via STAR) triplets during the same clinic visit.
Statistical analysis
A Bayesian GRM was fitted to calculate the latent grading thresholds between clinics and 
patients (Baldwin et al. 2009). In this analysis we focused on the model-based expected item 
responses between MDs, RNs, and patients. This model-based approach is advantageous in 
that it facilitates extraction of core information from data that contain multiple sources of 
variability. The resulting model-estimated responses then represent the most likely AE 
ratings from MDs, RNs, and patients with random error variabilities parsed out. The set of 
six individual AEs were treated as unidimensional, given that each AE was probed using a 
single item and independently rated by MDs, RNs, and patients.
It was necessary to code the data in a manner that was amenable to the GRM framework. 
Whereas the Baldwin example contained single ratings for each observation, the present 
dataset contains as many as three patient ratings and a clinic rating for each symptom. Table 
1 represents a single symptom example of the data structure in our analysis, with the 
columns representing scale items fitted. For each column, GRM item discrimination and 
thresholds were calculated. The posterior mean values of the model-fitted item responses 
were calculated to represent model-based AE grades obtained from MDs, RNs, and patients 
independently. Since all MDs and RNs did not assess AEs in all patients, instances where a 
given MD did not make a rating were treated as missing (noted by “N/A”). For example, 
MD 264 may have rated patients 004 and 390–393 but no other patients in the dataset. The 
Bayesian GRM approach updates the parameter estimates based on available data only; 
therefore, missing data provides no information with respect to the posterior distributions of 
the parameters. This permitted the modeling of decision thresholds across the aggregated 
clinic clusters in an actual clinical encounter, without the need to compel a rectangular data 
structure.
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With respect to the prior distributions, αs follow a Gaussian distribution with a mean of 1.0 
and a standard deviation of 2.5, truncated at a value >0.0. The threshold parameter κ values 
follow a Gaussian distribution of a mean of zero and a standard deviation of 2.5. The θ 
values were constrained to have a standard normal distribution. A total of 86,000 iterative 
burn-in simulations were completed, with the first 6000 iterations discarded, and thinning 
every ten simulations for the remaining 80,000 iterations. Other specific details on the 
Bayesian computation are explained elsewhere (Baldwin et al. 2009). Local independence 
among MD, RN, and patient ratings was assumed to simplify the illustrative examples. All 
analyses were completed using R version 3.2.3 (R Development Core Team 2016) and Just 
Another Gibbs Sampler (JAGS) version 4.1 (Plummer 2016). The RJAGS package was used 
in R as a conduit to send the data to JAGS for the actual simulations.
Results
Table 2 includes characteristics of the included patients (N = 393). Patients (median age = 
63, range = 26–91 years) were diagnosed with lung (34%), prostate (29%), or gynecologic 
(37%) malignancies; the majority of patients (85%) were high functioning (i.e., score 
≥80/100), as captured by the clinician-reported Karnofsky Performance Status (Karnofsky 
and Burchenal 1949) measure. These patients were independently rated by 1 of 26 attending 
oncologists and corresponding 26 RNs, without having access to each other’s assessments, 
as part of their routine clinic visit. The average amount of time between MD and RN ratings 
was 68.04 min (Atkinson et al. 2012).
Table 3 displays the means, standard deviations, and traditional concordance metrics for 
patient AE ratings, separated by comparisons of MDs and RNs, MDs and patients, and RNs 
and patients. ICCs less than 0.40 indicate poor agreement, values between 0.40 and 0.75 are 
indicative of moderate agreement, with values of 0.75 or higher indicating excellent 
agreement (Rosner 2005). Cohen’s κ estimates follow a similar convention, with values 
from 0.00 to 0.40 representing poor concordance, 0.41–0.75 indicating fair to good 
agreement, and values over 0.75 indicative of excellent agreement (Shrout and Fleiss 1979). 
For the current sample, Cohen’s κ and ICC estimates were poor to moderate at best when 
comparing any of these rating sources for each of the AEs. Additionally, the Cohen’s κ for 
the comparison between MD and patient ratings of constipation was −0.05, which cannot be 
meaningfully interpreted.
Figure 1 represents GRM estimates for MDs, RNs, patients, and the resulting difference 
between MD and patient, RN and patient, and MD and RN ratings for nausea. Each trace 
line represents the expected a posteriori (EAP) AE ratings made by each individual over a 
range of latent toxicity values. The upper left subplot of Fig. 1 displays the EAP MD 
CTCAE ratings for nausea. The upper center subplot of Fig. 1 displays the EAP RN CTCAE 
ratings for nausea. The upper right subplot displays the EAP STAR ratings for all patients 
for nausea.
The second row of subplots of Fig. 1 displays the differences between model-estimated 
patient and MD, RN and patient, and MD and RN EAP AE ratings for nausea. To interpret 
these subplots, a difference of zero would represent perfect concordance between raters, 
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with positive and negative values indicative of underestimation or overestimation of relative 
AE ratings, respectively. Here, MDs and RNs were observed to underestimate patient-
reported nausea, with a slight RN overestimation of nausea when compared to MD ratings. 
Further, the Bayesian GRM shows higher variability in patients’ thresholds in assessing 
nausea than those obtained from MDs and RN, as indicated by the more extreme trace lines 
for the patient versus MD and patient versus RN subplots.
The bottom subplots of Fig. 1 represent histograms of the GRM-estimated rating scale 
thresholds for nausea (i.e., Grade 0–1, 1–2, or 2–3), separated by MDs, RNs, and patients. 
For example, the subplot labeled “MD: Grade 0–1 Threshold” is the plot of the estimated 
thresholds for all 26 MDs, with the x-axis representing the latent implicit decision 
thresholds, in terms of standard deviations above or below the norm, and the y-axis 
representing the frequency count (i.e., the tallest bar represents four MDs with a latent 
implicit decision threshold near 0 standard deviations). The thick Gaussian kernel density 
trace line estimates represent the smooth versions of the histograms (Silverman 1986).
The MD and RN latent implicit decision threshold peak is represented by approximately five 
standard deviations above the norm, whereas the patient latent implicit decision threshold 
peak occurs at approximately four standard deviations above the norm. This implies that 
differences in AE grading between patients and MDs or RNs are more likely to occur at 
these higher levels of nausea toxicity.
Figure 2 represents constipation and follows the same general format as Fig. 1. Here, 
concordance between patients and MDs appears to be fairly high, with subtle MD 
underestimation at lower grading thresholds and overestimation at higher thresholds. RNs 
overestimate higher grading thresholds of patient- and MD-rated constipation. The 
frequency distribution subplots of Fig. 2 indicate that MD, RN, and patient latent implicit 
thresholds are relatively similar for the Grade 2–3 threshold, but that differences as large as 
1 or 2 grades occur when RNs rate constipation at the Grade 1–2 threshold, as compared to 
MDs. Appendix II includes similar figures for the remaining four AEs (i.e., diarrhea, 
dyspnea, fatigue, vomiting).
Discussion
Traditional methods of calculating concordance have been well established to characterize 
the relationship between two independent sources of information. However, when applying 
these methods to AE reporting, where there is likely to be a significant number of instances 
where MDs, RNs and patients agree due to a symptom not being present, the resulting 
coefficients may not be an accurate representation of the actual level of agreement. 
Additionally, a single coefficient does not provide us with a complete story of the 
relatedness of clinician- and patient-based AE ratings, particularly with respect to the 
direction and magnitude of the discrepancies. In the oncology clinical trial setting, where a 
difference as small as 1 CTCAE grade can determine whether a patient continues their 
participation in the trial, it is crucial to accurately identify and understand any sources of 
discrepancy in AE ratings. In this study, we used a Bayesian Graded Item Response Model 
to model concordance between MD-, RN,- and patient-based AE reporting, as well as 
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characterize potentially nuanced differences in AE grading thresholds between these three 
rating sources.
We found that on average, the disagreements between MDs, RNs, and patients were 
generally less than one grade, but in some instances, these discrepancies can vary by up to 
two grades. Overall, MDs and RNs underestimate patient-reported diarrhea, dyspnea, 
nausea, vomiting, and fatigue. The Bayesian GRM analysis also demonstrated that RNs 
overestimate higher levels (i.e., Grade 1–2) of constipation when compared to patient or MD 
ratings, which is consistent with previous findings from a study of patients undergoing 
chemotherapy (Cirillo et al. 2009).
Additionally, the Bayesian GRM indicated the presence of higher variability in the latent 
patient AE rating thresholds versus those obtained from MDs or RNs. This finding is 
consistent with our previous work that indicates clinician- based toxicity reports 
underestimate the frequency and severity of AEs when compared to patient reports of these 
AEs (Basch et al. 2009). Patient variability in their AE-reporting thresholds is likely due to 
the highly subjective and contextual nature of AE self-reporting, where a given patient’s 
rating of a severe AE could potentially be analogous to that same AE being rated as mild for 
another patient. Patients also may not be aware that important decisions related to their 
treatment and continued participation in a clinical trial may be impacted by their AE levels. 
As patient reporting of AEs becomes commonplace in oncology clinical trials, it may be 
important to provide patients with additional context with respect to the treatment-related 
implications of reporting a higher grade of a given AE.
The Bayesian GRM analysis begins to provide evidence to support the notion that patients 
report some symptoms that MDs and/or RNs might not consider to be important until the AE 
has reached a more elevated level of severity. This is important to understand as the 
inclusion of patient-reported AEs nears standardization in US-based clinical trials in 
oncology. Clinical trial participation can impact clinician AE grading. In such a case, 
assigning a higher AE grade for a particular symptom may result in that patient being 
removed from the trial, despite any other evidence of therapeutic benefit. Utilization of the 
Bayesian GRM visualization of differences in AE grading thresholds could be a potentially 
useful tool that would allow MDs and RNs to communicate and acknowledge differences 
between clinician and patient AE reports while explaining the implications of assigning a 
higher AE grade.
Given that patient reports of AEs are becoming increasingly accepted for inclusion in 
clinical trials, an outstanding issue could be related to which source of AE reports should be 
considered to be the definitive “gold standard” indicator of AE levels. In the present study, 
MD ratings were compared with RN ratings and patient ratings of AEs. While patients were 
mentioned as the reference category when compared to MDs or RNs, this was only for the 
point of illustrating differences between sources of AE ratings. Unfortunately, in the absence 
of standardized AE grading decision criteria for MDs, RNs, and patients, there may be no 
definitive “gold standard” source of AE information. Nevertheless, these multiple AE rating 
sources should be used as complementary pieces of information that can provide clinicians 
with a more complete picture of the patient symptomatic experience.
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This study is not without several limitations. Our sample was collected in a single, tertiary 
cancer center and was limited in diversity with respect to race, ethnicity, and disease type; 
only three cancer-type populations were included (i.e., lung, prostate, and gynecologic). 
Additionally, while the Bayesian GRM model is helpful in depicting underlying patterns of 
concordance between clinician- and patient-based AE ratings, this statistical method does 
not explain sources of discordance between raters. The STAR measure has been previously 
validated as a tool to capture patient-reported AEs (Basch et al. 2005); however, this 
instrument assesses a limited number of patient AEs. With the recent development of PRO-
CTCAE (Basch et al. 2014; Dueck et al. 2015; Hay et al. 2014), it follows that this Bayesian 
GRM analysis be used in a multicenter prospective study of patients across multiple disease 
types to assess a wide range of treatment-related AEs, as assessed by CTCAE and PRO-
CTCAE. Finally, in this context the GRM operates under the assumption that MD, RN, and 
patient ratings are locally independent given the model. As such, the results should be 
interpreted with caution, as non-independence may exist between these ratings. A formal 
investigation of this potential statistical codependence is beyond the scope of this article. 
Future applications of this analysis should accommodate the multi-level data structure (i.e., 
patients nested within RNs, who are nested within MDs) and potentially assess the utility of 
employing alternative models to accommodate such a structure, such as the Rasch testlet 
model (Wang and Wilson 2005).
The Bayesian GRM can be a potentially useful descriptive tool for understanding and 
visualizing the nuanced differences between MD-, RN-, and patient AE-reporting 
thresholds. For instances where MDs and RNs may rate the same patient or set of patients, 
the Bayesian GRM can display subtle patterns of discrepancies between such ratings and 
show where any potential large, 1–2 grade differences may exist for a given AE. This 
information can help to assist MDs and RNs in the standardization of AE grading. Similarly, 
as patient reports of treatment-related AEs become commonplace in oncology clinical trials, 
their ratings can be included in a Bayesian GRM framework to be displayed relative to their 
respective clinician ratings for a given AE. Such information can serve to enhance 
communication between patient and provider and potentially help patients understand the 
importance of accurate AE reporting, toward ultimately improving decisions related to 
treatment and long-term patient health outcomes.
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Fig. 1. 
Graded response model estimates and histograms for MDs, RNs, patients and the difference 
between MD, RN, and clinician thresholds for rating nausea. For the top two rows, each 
trace line represents the expected a posteriori (EAP) AE ratings made by each individual 
over a range of latent AE values. For the histograms, the thick Gaussian kernel density trace 
line estimates represent the smooth version of responses
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Fig. 2. 
Graded response model estimates and histograms for MDs, RNs, patients and the difference 
between MD, RN, and clinician thresholds for rating constipation. For the top two rows, 
each trace line represents the expected a posteriori (EAP) AE ratings made by each 
individual over a range of latent AE values. For the histograms, the thick Gaussian kernel 
density trace line estimates represent the smooth version of responses
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Table 2
Patient characteristics
Characteristic No. of patients (N = 393) %
Age range
Mean, years 62
Median, years 63
Gender
 Female 224 57
Cancer type
 Lung 134 34
 Prostate 113 29
 Gynecologic 146 37
Race/ethnicity
 African-American 25 7
 White Hispanic 11 3
 White Non-Hispanic 337 86
 Other 13 4
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